Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$565.00
-17.00 (-2.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-582.4M · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-27.7%
↓Gross Margin
49.3%
↑Debt/Equity
0.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-14.9%
FCF CAGR
—
FCF margin
-252.1%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $231.0M · net income $-763.8M · FCF $-582.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $231.0M | $231.0M | $54.4M | $61.1M | $374.5M |
| Net Income | $-763.8M | $-763.8M | $-872.2M | $-589.2M | $-474.0M |
| EBITDA | $-711.5M | $-711.5M | $-824.2M | $-538.3M | $-389.7M |
| EPS | — | — | -108.34 | -75.42 | -177.67 |
| Gross Margin | 49.3% | 49.3% | 30.9% | 61.8% | 64.5% |
| Operating Margin | -358.5% | -358.5% | -1645.9% | -1141.2% | -113.5% |
| Net Margin | -330.7% | -330.7% | -1602.0% | -964.1% | -126.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.48 | 0.48 | 0.34 | 0.29 | 0.24 |
| Current Ratio | 4.55 | 4.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-582.4M | $-582.4M | $-769.1M | $-581.8M | $-631.9M |
| Returns | |||||
| ROE | -27.7% | -27.7% | -34.3% | -18.4% | -12.6% |
| Valuation | |||||
| P/B | 1.97 | 1.97 | 1.43 | 1.80 | 0.89 |
| Growth & Yield | |||||
| Revenue Growth | 324.3% | 324.3% | -10.9% | -83.7% | — |
| EPS Growth | — | — | -43.6% | 57.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-38.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-108.34 → n/d
Residual
-38.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.